New MS drug shows promise in chinese trial

NCT ID NCT05199571

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug ofatumumab in 99 Chinese adults with relapsing multiple sclerosis (RMS). The goal was to see if monthly injections could reduce the number of relapses and monitor for side effects. Participants received the drug for 12 months, and researchers tracked relapse rates and MRI brain scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSING MULTIPLE SCLEROSIS

Contacts and locations

Locations

Novartis Investigative Site

Lanzhou, Gansu, 730030, China
Novartis Investigative Site

Guangzhou, Guangdong, 510000, China
Novartis Investigative Site

Guangzhou, Guangdong, 510080, China
Novartis Investigative Site

Guangzhou, Guangdong, 510630, China
Novartis Investigative Site

Shijiazhuang, Hebei, 050000, China
Novartis Investigative Site

Harbin, Heilongjiang, 150001, China
Novartis Investigative Site

Wuhan, Hubei, 430030, China
Novartis Investigative Site

Suzhou, Jiangsu, 215004, China
Novartis Investigative Site

Shenyang, Liaoning, 110011, China
Novartis Investigative Site

Taiyuan, Shanxi, 030001, China
Novartis Investigative Site

Ürümqi, Xinjiang, 830054, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310006, China
Novartis Investigative Site

Beijing, 065001, China
Novartis Investigative Site

Beijing, 100034, China
Novartis Investigative Site

Guangzhou, 510260, China
Novartis Investigative Site

Shanghai, 200025, China
Novartis Investigative Site

Shenzhen, 518036, China
Novartis Investigative Site

Tianjin, 300052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.